|This PCORI Funding Announcement will open on Thursday, January 3, 2019.|
This notice provides information about an upcoming Patient-Centered Outcomes Research Institute (PCORI) funding announcement (PFA), which will be released by PCORI on January 3, 2019. Through this initiative, PCORI seeks to fund high-quality clinical studies that compare the effectiveness of evidence-based psychological and/or pharmacological treatments for posttraumatic stress disorder (PTSD) in adults.
Previous research in PTSD has demonstrated the efficacy of many psychological interventions and some pharmacological treatments. However, few robust head-to-head, direct comparisons of evidence-based interventions have been completed to date. Studies that assess the heterogeneity of treatment effect within subgroups of interest (e.g., military versus civilian populations, men versus women, type of trauma, etc.) and those that include patients with comorbid conditions that frequently co-occur with PTSD (e.g., substance use disorder) are especially needed. The goal of this funding initiative is to support patient-centered comparative clinical effectiveness research to generate important findings about which specific treatments for adults with PTSD are most effective, and for whom.
For this PFA, the proposed comparators may include psychological interventions, pharmacological interventions, or a combination of the two. All proposed comparators must have demonstrated evidence of efficacy (from systematic reviews, prior empirical investigations, or other scientific documentation). Study endpoints should include patient-centered outcomes, such as functional outcomes and quality of life, in addition to symptom-related measures. Studies must include a minimum of 6 months of follow-up. PCORI is especially interested in studies that are inclusive of a broad patient population, including those with comorbidities, and in studies that are powered to assess the effectiveness of treatments in subgroups of interest.
The maximum project budget is $5 million in direct costs, with a maximum project duration of 3.5 years (42 months).
This PFA preannouncement is provided to allow potential applicants additional time to identify collaborators, obtain stakeholder input on the research question, and develop responsive, high-quality proposals. Further details will be available in the full announcement to be released on January 3, 2019.
Psychological and Pharmacological Treatments for Adults with Posttraumatic Stress Disorder (PTSD): A Systematic Review Update
A joint report from PCORI and the Agency for Healthcare Research and Quality outlines evidence-based therapies to curb PTSD symptoms.